nach oben

European Radiology

Erschienen in:

01.03.2011 | Urogenital

Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer

verfasst von: Tobias Franiel, Bernd Hamm, Hedvig Hricak

Erschienen in: European Radiology | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Dynamic contrast-enhanced MRI enables noninvasive analysis of prostate vascularization as well as tumour angiogenesis and capillary permeability characteristics in prostate cancers. Pharmacokinetic models summarizing the complex information provided by signal intensity-time curves for a few quantitative pharmacokinetic parameters are increasingly being used in the routine clinical setting. This review consists of two parts. The first part discusses the advantages and disadvantages of the MR pulse sequences that can be used for performing DCE-MRI and also of the most widely used pharmacokinetic parameters and models and the parameters they describe. The second part outlines the range of current and potential future clinical applications of DCE-MRI and pharmacokinetic parametric maps in patients with prostate cancer, with reference to the current scientific literature on the topic. The potential clinical applications of DCE-MRI for prostate cancer include detection, localization, and staging, differentiation of recurrent cancer and estimation of the patient’s prognosis, as well as monitoring of treatment response.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249CrossRefPubMed

Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT (2007) Imaging prostate cancer: a multidisciplinary perspective. Radiology 243:28–53CrossRefPubMed

Schiebler ML, Tomaszewski JE, Bezzi M et al (1989) Prostatic carcinoma and benign prostatic hyperplasia: correlation of high-resolution MR and histopathologic findings. Radiology 172:131–137PubMed

Beyersdorff D, Taupitz M, Winkelmann B et al (2002) Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. Radiology 224:701–706CrossRefPubMed

Sala E, Eberhardt SC, Akin O et al (2006) Endorectal MR imaging before salvage prostatectomy: tumor localization and staging. Radiology 238:176–183CrossRefPubMed

Coakley FV, Teh HS, Qayyum A et al (2004) Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 233:441–448CrossRefPubMed

Choi YJ, Kim JK, Kim N, Kim KW, Choi EK, Cho KS (2007) Functional MR imaging of prostate cancer. Radiographics 27:63–75, discussion 75–67CrossRefPubMed

Mirowitz SA, Brown JJ, Heiken JP (1993) Evaluation of the prostate and prostatic carcinoma with gadolinium-enhanced endorectal coil MR imaging. Radiology 186:153–157PubMed

Brown G, Macvicar DA, Ayton V, Husband JE (1995) The role of intravenous contrast enhancement in magnetic resonance imaging of prostatic carcinoma. Clin Radiol 50:601–606CrossRefPubMed

10.

Engelbrecht MR, Huisman HJ, Laheij RJ et al (2003) Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 229:248–254CrossRefPubMed

11.

Nicholson B, Schaefer G, Theodorescu D (2001) Angiogenesis in prostate cancer: biology and therapeutic opportunities. Cancer Metastasis Rev 20:297–319CrossRefPubMed

12.

Folkman J, Cole P, Zimmerman S (1996) Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg 164:491–502CrossRef

13.

Dewhirst MW, Tso CY, Oliver R, Gustafson CS, Secomb TW, Gross JF (1989) Morphologic and hemodynamic comparison of tumor and healing normal tissue microvasculature. Int J Radiat Oncol Biol Phys 17:91–99PubMed

14.

Pallares J, Rojo F, Iriarte J, Morote J, Armadans LI, de Torres I (2006) Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Histol Histopathol 21:857–865PubMed

15.

Bigler SA, Deering RE, Brawer MK (1993) Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol 24:220–226CrossRefPubMed

16.

Siegal JA, Yu E, Brawer MK (1995) Topography of neovascularity in human prostate carcinoma. Cancer 75:2545–2551CrossRefPubMed

17.

Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J (1993) Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143:401–409PubMed

18.

Silberman MA, Partin AW, Veltri RW, Epstein JI (1997) Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 79:772–779CrossRefPubMed

19.

Rubin MA, Buyyounouski M, Bagiella E et al (1999) Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome. Urology 53:542–547CrossRefPubMed

20.

Erbersdobler A, Isbarn H, Dix K et al (2010) Prognostic value of microvessel density in prostate cancer: a tissue microarray study. World J Urol 28:687–692CrossRefPubMed

21.

Concato J, Jain D, Li WW, Risch HA, Uchio EM, Wells CK (2007) Molecular markers and mortality in prostate cancer. BJU Int 100:1259–1263CrossRefPubMed

22.

Mucci LA, Powolny A, Giovannucci E et al (2009) Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol 27:5627–5633CrossRefPubMed

23.

Huisman HJ, Engelbrecht MR, Barentsz JO (2001) Accurate estimation of pharmacokinetic contrast-enhanced dynamic MRI parameters of the prostate. J Magn Reson Imaging 13:607–614CrossRefPubMed

24.

Hoffmann U, Brix G, Knopp MV, Hess T, Lorenz WJ (1995) Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography. Magn Reson Med 33:506–514CrossRefPubMed

25.

Prochnow D, Beyersdorff D, Warmuth C, Taupitz M, Gemeinhardt O, Lüdemann L (2005) Implementation of a rapid inversion-prepared dual-contrast gradient echo sequence for quantitative dynamic contrast-enhanced magnetic resonance imaging of the human prostate. Magn Reson Imaging 23:983–990CrossRefPubMed

26.

Taillieu F, Salomon LJ, Siauve N et al (2006) Placental perfusion and permeability: simultaneous assessment with dual-echo contrast-enhanced MR imaging in mice. Radiology 241:737–745CrossRefPubMed

27.

de Bazelaire C, Rofsky NM, Duhamel G et al (2006) Combined T2* and T1 measurements for improved perfusion and permeability studies in high field using dynamic contrast enhancement. Eur Radiol 16:2083–2091CrossRefPubMed

28.

Walker-Samuel S, Leach MO, Collins DJ (2007) Reference tissue quantification of DCE-MRI data without a contrast agent calibration. Phys Med Biol 52:589–601CrossRefPubMed

29.

Pintaske J, Martirosian P, Graf H et al (2006) Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol 41:213–221CrossRefPubMed

30.

Cheng HL, Wright GA (2006) Rapid high-resolution T(1) mapping by variable flip angles: accurate and precise measurements in the presence of radiofrequency field inhomogeneity. Magn Reson Med 55:566–574CrossRefPubMed

31.

Port RE, Knopp MV, Brix G (2001) Dynamic contrast-enhanced MRI using Gd-DTPA: interindividual variability of the arterial input function and consequences for the assessment of kinetics in tumors. Magn Reson Med 45:1030–1038CrossRefPubMed

32.

Rijpkema M, Kaanders JH, Joosten FB, van der Kogel AJ, Heerschap A (2001) Method for quantitative mapping of dynamic MRI contrast agent uptake in human tumors. J Magn Reson Imaging 14:457–463CrossRefPubMed

33.

Tofts PS, Brix G, Buckley DL et al (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10:223–232CrossRefPubMed

34.

Feldschuh J, Katz S (2007) The importance of correct norms in blood volume measurement. Am J Med Sci 334:41–46CrossRefPubMed

35.

Weinmann HJ, Laniado M, Mutzel W (1984) Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 16:167–172PubMed

36.

Fritz-Hansen T, Rostrup E, Larsson HB, Sondergaard L, Ring P, Henriksen O (1996) Measurement of the arterial concentration of Gd-DTPA using MRI: a step toward quantitative perfusion imaging. Magn Reson Med 36:225–231CrossRefPubMed

37.

Parker GJ, Roberts C, Macdonald A et al (2006) Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. Magn Reson Med 56:993–1000CrossRefPubMed

38.

Port RE, Knopp MV, Hoffmann U, Milker-Zabel S, Brix G (1999) Multicompartment analysis of gadolinium chelate kinetics: blood-tissue exchange in mammary tumors as monitored by dynamic MR imaging. J Magn Reson Imaging 10:233–241CrossRefPubMed

39.

Brix G, Semmler W, Port R, Schad LR, Layer G, Lorenz WJ (1991) Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 15:621–628CrossRefPubMed

40.

Brix G, Schreiber W, Hoffmann U, Guckel F, Hawighorst H, Knopp MV (1997) Methodological approaches to quantitative evaluation of microcirculation in tissues with dynamic magnetic resonance tomography. Radiologe 37:470–480CrossRefPubMed

41.

Tofts PS, Kermode AG (1991) Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 17:357–367CrossRefPubMed

42.

Tofts PS, Berkowitz B, Schnall MD (1995) Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn Reson Med 33:564–568CrossRefPubMed

43.

Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029–1039PubMed

44.

Gerlowski LE, Jain RK (1986) Microvascular permeability of normal and neoplastic tissues. Microvasc Res 31:288–305CrossRefPubMed

45.

St. Lawrence KS, Lee TY (1998) An adiabatic approximation to the tissue homogeneity model for water exchange in the brain: II. experimental validation. J Cereb Blood Flow Metab 18:1378–1385CrossRefPubMed

46.

Kershaw LE, Buckley DL (2006) Precision in measurements of perfusion and microvascular permeability with T1-weighted dynamic contrast-enhanced MRI. Magn Reson Med 56:986–992CrossRefPubMed

47.

Lüdemann L, Prochnow D, Rohlfing T et al (2009) Simultaneous quantification of perfusion and permeability in the prostate using dynamic contrast-enhanced magnetic resonance imaging with an inversion-prepared dual-contrast sequence. Ann Biomed Eng 37:749–762CrossRefPubMed

48.

Stephenson JL (1948) Theory of the measurement of blood flow by the dilution of an indicator. Bull Math Biophys 10:117–121CrossRefPubMed

49.

American Urological Association (2007) Guideline for management of clinically localized prostate cancer: 2007 update. In. http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/proscan07/content.pdf, 2007

50.

Keetch DW, Catalona WJ, Smith DS (1994) Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 151:1571–1574PubMed

51.

Roehl KA, Antenor JA, Catalona WJ (2002) Serial biopsy results in prostate cancer screening study. J Urol 167:2435–2439CrossRefPubMed

52.

Langer DL, van der Kwast TH, Evans AJ, Trachtenberg J, Wilson BC, Haider MA (2009) Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging 30:327–334CrossRefPubMed

53.

Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S (2007) Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 25:146–152CrossRefPubMed

54.

* Franiel T, Lüdemann L, Rudolph B, et al (2009) Prostate MR imaging: tissue characterization with pharmacokinetic volume and blood flow parameters and correlation with histologic parameters. Radiology 252:101–108

55.

Cheikh AB, Girouin N, Colombel M et al (2009) Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy. Eur Radiol 19:770–778CrossRefPubMed

56.

* Hambrock T, Futterer JJ, Huisman HJ et al (2008) Thirty-two-channel coil 3T magnetic resonance-guided biopsies of prostate tumor suspicious regions identified on multimodality 3T magnetic resonance imaging: technique and feasibility. Invest Radiol 43:686–694

57.

Xu S, Kruecker J, Turkbey B et al (2008) Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies. Comput Aided Surg 13:255–264PubMed

58.

Hricak H, Wang L, Wei DC et al (2004) The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy. Cancer 100:2655–2663CrossRefPubMed

59.

* Jackson AS, Reinsberg SA, Sohaib SA, et al (2009) Dynamic contrast-enhanced MRI for prostate cancer localization. Br J Radiol 82:148–156

60.

* Futterer JJ, Heijmink SW, Scheenen TW et al (2006) Prostate Cancer Localization with Dynamic Contrast-enhanced MR Imaging and Proton MR Spectroscopic Imaging. Radiology 241:449–458

61.

* Ocak I, Bernardo M, Metzger G et al (2007) Dynamic contrast-enhanced MRI of prostate cancer at 3T: a study of pharmacokinetic parameters. AJR Am J Roentgenol 189:849

62.

Beyersdorff D, Taymoorian K, Knosel T et al (2005) MRI of prostate cancer at 1.5 and 3.0T: comparison of image quality in tumor detection and staging. AJR Am J Roentgenol 185:1214–1220CrossRefPubMed

63.

Heijmink SW, Futterer JJ, Hambrock T et al (2007) Prostate cancer: body-array versus endorectal coil MR imaging at 3T—comparison of image quality, localization, and staging performance. Radiology 244:184–195CrossRefPubMed

64.

Bloch BN, Furman-Haran E, Helbich TH et al (2007) Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging–initial results. Radiology 245:176–185CrossRefPubMed

65.

D’Amico AV, Whittington R, Malkowicz SB et al (2002) Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 95:281–286CrossRefPubMed

66.

Kestin LL, Vicini FA, Ziaja EL, Stromberg JS, Frazier RC, Martinez AA (1999) Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy. Cancer 86:1557–1566CrossRefPubMed

67.

Pound CR, Brawer MK, Partin AW (2001) Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer. Rev Urol 3:72–84PubMed

68.

Nudell DM, Wefer AE, Hricak H, Carroll PR (2000) Imaging for recurrent prostate cancer. Radiol Clin North Am 38:213–229CrossRefPubMed

69.

Sella T, Schwartz LH, Swindle PW et al (2004) Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 231:379–385CrossRefPubMed

70.

Cirillo S, Petracchini M, Scotti L et al (2009) Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol 19:761–769CrossRefPubMed

71.

Haider MA, Chung P, Sweet J et al (2008) Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 70:425–430CrossRefPubMed

72.

Rouviere O, Valette O, Grivolat S et al (2004) Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor–correlation with biopsy findings. Urology 63:922–927CrossRefPubMed

73.

* Yakar D, Hambrock T, Huisman H et al (2010) Feasibility of 3T dynamic contrast-enhanced magnetic resonance-guided biopsy in localizing local recurrence of prostate cancer after external beam radiation therapy. Invest Radiol 45:121–125

74.

* Moman MR, van den Berg CA, Boeken Kruger AE et al (2010) Focal salvage guided by T2-weighted and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer recurrences. Int J Radiat Oncol Biol Phys 76:741–746

75.

Casciani E, Polettini E, Carmenini E et al (2008) Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. AJR Am J Roentgenol 190:1187–1192CrossRefPubMed

76.

Zand KR, Reinhold C, Haider MA, Nakai A, Rohoman L, Maheshwari S (2007) Artifacts and pitfalls in MR imaging of the pelvis. J Magn Reson Imaging 26:480–497CrossRefPubMed

77.

Rouviere O, Girouin N, Glas L et al (2010) Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI. Eur Radiol 20:48–55CrossRefPubMed

78.

Schroder FH, Hugosson J, Roobol MJ et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320–1328CrossRefPubMed

79.

Choo R, Klotz L, Danjoux C et al (2002) Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 167:1664–1669CrossRefPubMed

80.

Dall’Era MA, Cooperberg MR, Chan JM et al (2008) Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 112:1650–1659CrossRefPubMed

81.

Coakley FV, Chen I, Qayyum A et al (2007) Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging. BJU Int 99:41–45CrossRefPubMed

82.

Kulkarni GS, Lockwood G, Evans A et al (2007) Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy. Cancer 109:2432–2438CrossRefPubMed

83.

Poulos CK, Daggy JK, Cheng L (2004) Prostate needle biopsies: multiple variables are predictive of final tumor volume in radical prostatectomy specimens. Cancer 101:527–532CrossRefPubMed

84.

Wang L, Mazaheri Y, Zhang J, Ishill NM, Kuroiwa K, Hricak H (2008) Assessment of biologic aggressiveness of prostate cancer: correlation of MR signal intensity with Gleason grade after radical prostatectomy. Radiology 246:168–176CrossRefPubMed

85.

* Franiel T, Lüdemann L, Taupitz M, Rost J, Asbach P, Beyersdorff D (2009) Pharmacokinetic MRI of the prostate: parameters for differentiating low-grade and high-grade prostate cancer. Rofo 181:536–542

86.

* Schlemmer HP, Merkle J, Grobholz R et al (2004) Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? Eur Radiol 14:309–317

87.

* Kiessling F, Lichy M, Grobholz R et al (2004) Simple models improve the discrimination of prostate cancers from the peripheral gland by T1-weighted dynamic MRI. Eur Radiol 14:1793–1801

88.

Roach M 3rd (2003) Commentary on a multi-institutional analysis of external beam radiotherapy for T1-T2 prostate cancer: “love the one you’re with” and “do the right thing”. Int J Radiat Oncol Biol Phys 57:907–909CrossRefPubMed

89.

Takamiya R, Weinberg V, Young CD, Sandler H, McLaughlin P, Roach M 3rd (2003) A zero PSA slope in posttreatment prostate-specific antigen supports cure of patients with long-term follow-up after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 56:1073–1078CrossRefPubMed

90.

Hanlon AL, Pinover WH, Horwitz EM, Hanks GE (2001) Patterns and fate of PSA bouncing following 3D-CRT. Int J Radiat Oncol Biol Phys 50:845–849CrossRefPubMed

91.

Cavanagh W, Blasko JC, Grimm PD, Sylvester JE (2000) Transient elevation of serum prostate-specific antigen following (125)I/(103)Pd brachytherapy for localized prostate cancer. Semin Urol Oncol 18:160–165PubMed

92.

Pickett B, Kurhanewicz J, Coakley F, Shinohara K, Fein B, Roach M 3rd (2004) Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 60:1047–1055CrossRefPubMed

93.

* Franiel T, Lüdemann L, Taupitz M, Bohmer D, Beyersdorff D (2009) MRI before and after external beam intensity-modulated radiotherapy of patients with prostate cancer: the feasibility of monitoring of radiation-induced tissue changes using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence. Radiother Oncol 93:241–245

94.

* Padhani AR, MacVicar AD, Gapinski CJ et al (2001) Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with MR imaging. Radiology 218:365–374

95.

* Jia G, Heverhagen JT, Henry H et al (2006) Pharmacokinetic parameters as a potential predictor of response to pharmacotherapy in benign prostatic hyperplasia: a preclinical trial using dynamic contrast-enhanced MRI. Magn Reson Imaging 24:721–725

96.

* Maxwell RJ, Wilson J, Prise VE et al (2002) Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed 15:89–98

97.

* Franiel T, Lüdemann L, Rudolph B et al (2008) Evaluation of normal prostate tissue, chronic prostatitis, and prostate cancer by quantitative perfusion analysis using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence. Invest Radiol 43:481–487

98.

Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:967–974CrossRefPubMed

99.

Kluetz PG, Figg WD, Dahut WL (2010) Angiogenesis inhibitors in the treatment of prostate cancer. Expert Opin Pharmacother 11:233–247CrossRefPubMed

100.

Tsao J, Hansen MS, Kozerke S (2006) Accelerated parallel imaging by transform coding data compression with k-t SENSE. Conf Proc IEEE Eng Med Biol Soc 1:372CrossRefPubMed

Titel: Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer
verfasst von: Tobias Franiel
Bernd Hamm
Hedvig Hricak
Publikationsdatum: 01.03.2011
Verlag: Springer-Verlag
Erschienen in: European Radiology / Ausgabe 3/2011
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-010-2037-7

Neu im Fachgebiet Radiologie

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer

Abstract

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Quantitative Angiografie könnte IVUS-Alternative darstellen

Update Radiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

An unusual case of pancreatic and gastric neoplasms (2010: 12b)

Experimental studies investigating the pathophysiology of nephrogenic systemic fibrosis; what did we learn so far?

Editorial for anniversary issue of European Radiology

Assessment of tissue perfusion by contrast-enhanced ultrasound

High-risk lesions diagnosed at MRI-guided vacuum-assisted breast biopsy: can underestimation be predicted?

Musculoskeletal imaging: current and future trends

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Quantitative Angiografie könnte IVUS-Alternative darstellen

Update Radiologie